CURE attended the Hairy Cell Leukemia Foundation 2025 Conference where medical experts gathered to discuss advances in research and patient care. CURE had the privilege of attending the Hairy Cell ...

CURE sat down with Dr. Kerry A. Rogers for an interview at the Hairy Cell Leukemia Foundation 2025 Conference, hosted in Bologna, Italy. We sat down with Dr. Kerry A. Rogers for an interview at the ...

Hairy cell leukaemia (HCL) remains an intriguing B‐cell malignancy defined by its distinctive “hairy” cytoplasmic projections and its unique pattern of bone marrow infiltration. Recent research has ...

Combination Therapy With Olaparib Plus Lenvatinib in a Patient With BRCA2-Mutated, Radioiodine-Refractory, Metastatic Papillary Thyroid Cancer: A Case Report The following represents disclosure ...

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): ...

Scientists in Japan have discovered a genetic "silencer" within the HTLV-1 virus that helps it stay hidden in the body, evading the immune system for decades. This silencer element essentially turns ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

Results from the largest report ever on young hairy cell leukemia (HCL) patients treated with standard chemotherapy — cladribine — are a mixed bag. On the one hand, a majority of the 83 patients, all ...

A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...